Custom Pharma Services
Chris Davison currently holds the position of Chief Executive Officer at Custom Pharma Services since March 2021, while also serving as Technical Director. Prior to this role, Chris Davison spent over two decades at GSK from July 1998 to March 2021, where responsibilities included Technical Director for Oral Solid Dose & Micronising, overseeing new product introduction and the commercial supply of medicines. Additional roles at GSK encompassed Product Owner & Technical Operations Manager, Product Development Manager, CMC Technical Leader, and Product Development Scientist, demonstrating a strong background in pharmaceutical development and operations. Chris Davison earned a Bachelor of Pharmacy (B.Pharm.) degree from the University of Bradford between 1994 and 1998.
This person is not in any teams
Custom Pharma Services
1 followers
Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities